Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Genedrive ( (GB:GDR) ) has provided an update.
Genedrive plc’s CYP2C19 ID Kit is set to be implemented at North Bristol NHS Trust’s Southmead Hospital Hyperacute and Acute Stroke Units, backed by £80,000 in funding from the Medlock Charitable Trust, whose chair David Medlock is a major shareholder in the company. The deployment targets around 1,500 stroke patients treated annually at Southmead and is intended to optimise clopidogrel use by rapidly identifying patients who are unlikely to respond to the standard antiplatelet therapy.
The funding will be channelled through Southmead Hospital Charity, which supports care enhancements beyond standard NHS provision, while the hospital’s stroke services prepare a business case to secure ongoing local ICB financing once the initial phase ends. Senior figures from Genedrive, the Medlock Charitable Trust and Bristol NHS highlighted that the partnership introduces cutting-edge, point-of-care genotype testing for stroke secondary prevention, aiming to individualise treatment, improve long-term outcomes and potentially reduce healthcare costs, strengthening Genedrive’s position within NHS precision medicine pathways.
Spark’s Take on GDR Stock
According to Spark, TipRanks’ AI Analyst, GDR is a Neutral.
The score is held back primarily by weak financial performance—large ongoing losses, sustained cash burn, and a shrinking equity base despite minimal debt. Technicals are moderately supportive with price above key moving averages and positive MACD, but elevated RSI signals near-term overheating risk. Valuation remains challenging due to negative earnings (negative P/E).
To see Spark’s full report on GDR stock, click here.
More about Genedrive
Genedrive plc is a UK-based, commercial-stage pharmacogenetic testing company specialising in rapid, point-of-care diagnostic kits that guide safer and more effective drug prescribing in emergency and acute care. Its CE-IVD approved and NICE-recommended tests include the Genedrive CYP2C19 ID Kit for optimising antiplatelet therapy in stroke patients and the MT-RNR1 ID Kit to prevent antibiotic-induced hearing loss in newborns, underpinning its push to embed precision diagnostics into routine NHS care and support future international growth.
Average Trading Volume: 5,796,825
Technical Sentiment Signal: Strong Sell
Current Market Cap: £15.25M
For an in-depth examination of GDR stock, go to TipRanks’ Overview page.